A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer Meeting Abstract
| Authors: | Beeram, M.; Tolaney, S. M.; Beck, J. T.; Dickler, M. N.; Conlin, A. K.; Dees, C.; Helsten, T. L.; Conkling, P. R.; Edenfield, W. J.; Richards, D. A.; Kambhampati, S. R. P.; Costigan, T. M.; Chan, E.; Pant, S.; Kalinsky, K.; Burris, H. A.; Becerra, C. H.; Rexer, B. N.; Puhalla, S. L.; Goetz, M. P. |
| Abstract Title: | A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer |
| Meeting Title: | 41st European Society for Medical Oncology Congress (ESMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 27 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2016 Oct 7-11 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2016-10-01 |
| Start Page: | vi556 |
| Language: | English |
| ACCESSION: | WOS:000393913000697 |
| DOI: | 10.1093/annonc/mdw435.08 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA18 -- Source: Wos |
